Axsome Therapeutics
Axsome Therapeutics, Inc. is an American commercial-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) disorders. The company focuses its operational efforts on research, clinical trials, and commercial sales of small molecule therapeutics for psychiatric and neurological conditions. Its commercial product lineup features Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness, alongside late-stage clinical pipelines for Alzheimer's agitation and migraine. Primary revenue is derived from product sales of its commercial CNS pharmaceuticals in the United States alongside licensing royalties. Axsome Therapeutics holds an established position as an innovative biopharmaceutical firm in central nervous system medicine. The company is headquartered in New York City, New York, and its shares trade on the Nasdaq Global Select Market.
10 of the funds FundTelligence covers report a position in Axsome Therapeutics.
- Legal name
- Axsome Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 10
- Exposure themes
- Depression & Mood Disorders, Mental Health, Multiple, Psychiatry, Treatment, Women's Health
Funds holding Axsome Therapeutics
- DNB Bioteknologi — DNB · 4.39 % (full portfolio disclosed, September 2026)
- DNB Fund Women's Health — DNB · 2.11 % (full portfolio disclosed, August 2026)
- DNB Health Care — DNB · 1.87 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.52 % (full portfolio disclosed, October 2026)
- Fondsfinans Global Helse — Fondsfinans · 0.5 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.45 % (full portfolio disclosed, October 2026)
- Handelsbanken Helse Tema — Handelsbanken · 0.21 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.09 % (partially disclosed portfolio, June 2026)
Showing the 8 largest of 10 funds holding it.